Both MiaPaCa-2 (insensitive to CuB) and ASPC-1 (sensitive to CuB) have Ras and p53 mutations, which occur in 90% and 50–75% of pancreatic cancer patients, respectively, and can activate multiple signaling pathways related to cell proliferation and anti-apoptosis [37, 38]. The gene discussed is TP53; the disease is pancreatic neoplasm.